Kenta Biotech AG
  • Home
  • Shop
  • Events
  • Courses
  • Services
  • Pricing
  • Company
    • Blog
    • Success Stories
    • About Us
  • Appointment
  • Contact us
  • 0
  • +1 (718) 513-2983
  • Sign in
  • Contact Us
Kenta Biotech AG
  • 0
    • Home
    • Shop
    • Events
    • Courses
    • Services
    • Pricing
    • Company
      • Blog
      • Success Stories
      • About Us
    • Appointment
    • Contact us
  • +1 (718) 513-2983
  • Sign in
  • Contact Us
  1. Products
  2. NATtrol Controls
Public Pricelist
Public Pricelist
Sort By: Featured
Featured Newest Arrivals Name (A-Z) Price - Low to High Price - High to Low

NATtrol Controls

[0920-IST-N502] Strep A Rapid Test Cassette (Control Line in Red) 20T/Test
Strep A Rapid Test Cassette (Control Line in Red) 20T/Test
335.00 € 335.0 EUR
[0521-IM9701] Spoligotyping Test with Primers and Controls
Spoligotyping Test with Primers and Controls
1,980.00 € 1980.0 EUR
[0131-SO809c] Soft tissue sarcoma as control, including TNM, clinical stage and pathology grade, 80 cases/80 cores(core size 1.5mm), replacing SO809b  unstained, fresh cut, unbaked
Soft tissue sarcoma as control, including TNM, clinical stage and pathology grade, 80 cases/80 cores(core size 1.5mm), replacing SO809b unstained, fresh cut, unbaked
304.00 € 304.0 EUR
[0131-ME811] Skin malignant melanoma tissue array with adjacent skin tissue as control, including TNM, clinical stage, 42 cases/ 81 cores
Skin malignant melanoma tissue array with adjacent skin tissue as control, including TNM, clinical stage, 42 cases/ 81 cores
385.00 € 385.0 EUR
[0444-F653S-SPC] Simple Plex HEK293 HCP Controls (F653S-SPC)
Simple Plex HEK293 HCP Controls (F653S-SPC)
787.00 € 787.0 EUR
[0173-05FK10C] SD Malaria Positive and Negative Controls
SD Malaria Positive and Negative Controls
75.00 € 75.0 EUR
[0002-NATFRC-6C] SARS-COV-2 Positive Control Flu/RSV (6 x 0.5 mL)
SARS-COV-2 Positive Control Flu/RSV (6 x 0.5 mL)
362.50 € 362.5 EUR
[0002-KZMC036] Rotavirus Rapid Test Control Pack (2 X 1.5mL)
Rotavirus Rapid Test Control Pack (2 X 1.5mL)
371.00 € 371.0 EUR
[MBS536524-5ml] Rheumatoid Factor Positive Control Immunoglobulin - 5ml
Rheumatoid Factor Positive Control Immunoglobulin - 5ml
489.00 € 489.0 EUR
[MBS536524-100ml] Rheumatoid Factor Positive Control Immunoglobulin - 100ml
Rheumatoid Factor Positive Control Immunoglobulin - 100ml
1,426.00 € 1426.0 EUR
[0118-35-RC25] Rheumatoid Factor Positive Control
Rheumatoid Factor Positive Control
1,249.60 € 1249.6000000000001 EUR
[0544-MBS318698] Rheumatoid Factor Control Serum 1ml
Rheumatoid Factor Control Serum 1ml
379.00 € 379.0 EUR
[0556-N15-MC110] Respiratory swab matric neg control  10 vials
Respiratory swab matric neg control 10 vials
457.50 € 457.5 EUR
[0002-KZMC034] Respiratory Syncytial Virus (RSV) Rapid Test Control Pack (2 X 1.5mL)
Respiratory Syncytial Virus (RSV) Rapid Test Control Pack (2 X 1.5mL)
303.00 € 303.0 EUR
[0002-NATRPC2.1-BIO] Respiratory Panel 2.1 (RP2.1) Controls (12 x 0.3mL)
Respiratory Panel 2.1 (RP2.1) Controls (12 x 0.3mL)
621.75 € 621.75 EUR
[0015-PAI21-R-25] Recombinnat purified Human Plasminogen Activator Inhibitor 1 (PAI-1) protein (his-tag) control for ELISA - 25 ug.
Recombinnat purified Human Plasminogen Activator Inhibitor 1 (PAI-1) protein (his-tag) control for ELISA - 25 ug.
440.00 € 440.0 EUR
  • 5
  • 6
  • 7
  • 8
  • 9

Clear Filters



Respiratory syncytial virus (RSV) infections are the most common cause of hospitalization in early childhood, accounting for 57 000 to 120 000 hospitalizations each year in the United States. RSV is causing annual epidemics of bronchiolitis and pneumonia worldwide. In most cases the infection with RSV heals without sequelae, yet RSV infection can cause lung function deterioration and in some circumstances, years of recurrent wheezing or asthma may ensue. Overall RSV accounts for an estimated2% of the hospitalization rate among infants less than 1 year of age. This rate increases 4–5-fold among high-risk patients such as premature infants and those with chronic lung disease or complicated congenital heart disease.


Currently there is only one possibility to prevent infections of at-risk patients with RSV, namely immuno-prophylaxis with palivizumab/Synagis, marketed by MedImmune. However, the response to palivizumab is variable among individuals, and sometimes palivizumab fails to prevent RSV infections effectively.


Due to the lack of better antibodies, lack of effective anti-viral treatment and lack of an effective preventive vaccine for RSV, there is a substantial medical need for more efficacious prophylactic immunizations, e.g. by antibody.


Kenta Biotech had developed a fully human monoclonal antibody (KBRV201) derived from B-cells of a human donor. KBRV201 is of the human IgG1 isotype with specificity and very high affinity for the F-protein of human respiratory syncytial virus (hRSV). KBRV201 has been tested for recognition and neutralization of hRSV strains -A, -B and –Long, and KBRV201 could neutralize in vitro all strains tested with higher efficacy than other anti-F-protein mAb.




KBRV201 successfully recognizes 22 clinical isolates from children infected with RSV, including one isolate with a mutated F-protein. Overall KBRV201 has demonstrated superiority in every experiment performed, and KBRV201 is currently undergoing extensive testing in animal models.

14009 NW Harbor Ln, Portland, OR 97229, USA.


Follow us
Copyright © 2025 Kenta Biotech AG
English (UK) English (US)